194 related articles for article (PubMed ID: 24356289)
1. [Aggressive and resistant-to-treatment pituitary tumors].
Cuny T; Chanson P
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S3-12. PubMed ID: 24356289
[TBL] [Abstract][Full Text] [Related]
2. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
[TBL] [Abstract][Full Text] [Related]
3. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
[TBL] [Abstract][Full Text] [Related]
5. Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?
Solari D; Pivonello R; Caggiano C; Guadagno E; Chiaramonte C; Miccoli G; Cavallo LM; Del Basso De Caro M; Colao A; Cappabianca P
World Neurosurg; 2019 Jul; 127():695-709. PubMed ID: 31266132
[TBL] [Abstract][Full Text] [Related]
6. [Indications for surgical treatment of prolactin-secreting pituitary adenomas].
Kalinin PL; Astaf'eva LI; Kadashev BA; Ismailov DB
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(5):117-124. PubMed ID: 29076475
[TBL] [Abstract][Full Text] [Related]
7. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation.
Lania AG; Ferrero S; Pivonello R; Mantovani G; Peverelli E; Di Sarno A; Beck-Peccoz P; Spada A; Colao A
J Clin Endocrinol Metab; 2010 Jan; 95(1):13-7. PubMed ID: 19890024
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.
Daly AF; Rixhon M; Adam C; Dempegioti A; Tichomirowa MA; Beckers A
J Clin Endocrinol Metab; 2006 Dec; 91(12):4769-75. PubMed ID: 16968795
[TBL] [Abstract][Full Text] [Related]
10. Therapy of aggressive pituitary tumors.
Colao A; Grasso LF; Pivonello R; Lombardi G
Expert Opin Pharmacother; 2011 Jul; 12(10):1561-70. PubMed ID: 21434849
[TBL] [Abstract][Full Text] [Related]
11. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype.
Chen Y; Gao H; Xie W; Guo J; Fang Q; Zhao P; Liu C; Zhu H; Wang Z; Wang J; Gui S; Zhang Y; Li C
Aging (Albany NY); 2020 Dec; 13(1):1276-1293. PubMed ID: 33472173
[TBL] [Abstract][Full Text] [Related]
12. Management of prolactinomas during pregnancy.
Witek P; Zieliński G
Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
[TBL] [Abstract][Full Text] [Related]
13. [Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?].
Marek J
Vnitr Lek; 2010 Jul; 56(7):690-4. PubMed ID: 20842914
[TBL] [Abstract][Full Text] [Related]
14. Medical approach to pituitary tumors.
Neggers SJ; van der Lely AJ
Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
[TBL] [Abstract][Full Text] [Related]
15. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion.
Trouillas J; Daniel L; Guigard MP; Tong S; Gouvernet J; Jouanneau E; Jan M; Perrin G; Fischer G; Tabarin A; Rougon G; Figarella-Branger D
J Neurosurg; 2003 May; 98(5):1084-93. PubMed ID: 12744370
[TBL] [Abstract][Full Text] [Related]
16. Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors.
Raverot G; Vasiljevic A; Jouanneau E; Lasolle H
Eur J Endocrinol; 2019 Aug; 181(2):C1-C3. PubMed ID: 31167164
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
Fusco A; Zatelli MC; Bianchi A; Cimino V; Tilaro L; Veltri F; Angelini F; Lauriola L; Vellone V; Doglietto F; Ambrosio MR; Maira G; Giustina A; degli Uberti EC; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2008 Jul; 93(7):2746-50. PubMed ID: 18460561
[TBL] [Abstract][Full Text] [Related]
18. Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects.
Mercado M; Melgar V; Salame L; Cuenca D
Endocrinol Diabetes Nutr; 2017; 64(7):384-395. PubMed ID: 28745610
[TBL] [Abstract][Full Text] [Related]
19. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells.
Roche C; Rasolonjanahary R; Thirion S; Goddard I; Fusco A; Figarella-Branger D; Dufour H; Brue T; Franc JL; Enjalbert A; Barlier A
Hum Gene Ther; 2012 Jan; 23(1):104-14. PubMed ID: 21942649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
